GMGuadalupe Muñoz‐Arenas

Guadalupe Muñoz‐Arenas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Guadalupe Muñoz‐Arenas has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    El riesgo de la baja académica, desde la voz de los estudiantes. El caso de una Licenciatura en Farmacia

    by Luis Ángel Aguilar-Carrasco, María de Guadalupe Muñoz-Arenas, Dulce María Carolina Flores-Olvera, Itxel Cid-Polo

    La deserción escolar es un fenómeno complejo que suele abordarse desde la visión cuantitativa, en el presente proyecto se buscó dar voz a un grupo de personas que se encontraban en riesgo de ser dadas de baja de la Licenciatura en Farmacia en la institución en la que se encuentran inscritos, se cotejaron los datos de baja del Programa Educativo por cohorte generacional para posteriormente entrevistar a aquellas personas que cumplieran con alguno de los criterios que los clasificaran como riesgo de baja, se recogió información entorno a cuáles razones les habían impedido culminar la carrera, su situación familiar, económica, relación con docentes y percepción sobre el programa educativo.

  • Open Access

    Los perfiles profesionales del QFB en México

    by Luis Angel Aguilar Carrasco, María Luisa Roxana Licona Ibarra, Laura Morales Lara, María de Guadalupe Muñoz Arenas

    The review of the graduate profiles reported by eighteen higher education institutions was carried out, all of them have a career identified as “Químico Farmacobiólogo” or one of the names that in the catalog of recognized subjects in Mexico are considered as similar to this area. From the comparative profiles, we analyzed the common areas of knowledge, those that distinguish each program, as well as emerging areas that may be presented in the teaching of this educational program, to conclude from the sociology of occupations whether or not graduates of these educational programmes can be considered as professionals from the written definition of the concept.

  • Gallic acid improves recognition memory and decreases oxidative‐inflammatory damage in the rat hippocampus with metabolic syndrome

    by Alfonso Diaz, Guadalupe Muñoz‐Arenas, Karen Caporal‐Hernandez, Rubén Vázquez‐Roque, Gustavo Lopez‐Lopez, Anna Kozina, Blanca Espinosa, Gonzalo Flores, Samuel Treviño, Jorge Guevara

    Metabolic syndrome (MS) results from excessive consumption of high‐calorie foods and sedentary lifestyles. Clinically, insulin resistance, abdominal obesity, hyperglycemia, dyslipidemia, and hypertension are observed. MS has been considered a risk factor in the development of dementia. In the brain, a metabolically impaired environment generates oxidative stress and excessive production of pro‐inflammatory cytokines that deteriorate the morphology and neuronal function in the hippocampus, leading to cognitive impairment. Therapeutic alternatives suggest that phenolic compounds can be part of the treatment for neuropathies and metabolic diseases. In recent years, the use of Gallic Acid (GA) has demonstrated antioxidant and anti‐inflammatory effects that contribute to neuroprotection and memory improvement in animal models. However, the effect of GA on hippocampal neurodegeneration and memory impairment under MS conditions is still unclear. In this work, we administered GA (20 mg/kg) for 60 days to rats with MS. The results show that GA treatment improved zoometric and biochemical parameters, as well as the recognition memory, in animals with MS. Additionally, GA administration increased hippocampal dendritic spines and decreased oxidative stress and inflammation. Our results show that GA treatment improves metabolism: reducing the oxidative and inflammatory environment that facilitates the recovery of the neuronal morphology in the hippocampus of rats with MS. Consequently, the recognition of objects by these animals, suggesting that GA could be used therapeutically in metabolic disorders that cause dementia.


  • Effects of metformin on recognition memory and hippocampal neuroplasticity in rats with metabolic syndrome

    by Guadalupe Muñoz‐Arenas, Guadalupe Pulido, Samuel Treviño, Rubén Vázquez‐Roque, Gonzalo Flores, Carolina Moran, Anabella Handal‐Silva, Jorge Guevara, Berenice Venegas, Alfonso Díaz

    Metabolic syndrome (MS) is a health problem that is characterized by body fat accumulation, hypertension, dyslipidemia, and hyperglycemia; recently, it has been demonstrated that MS also damages memory processes. The first‐line drug in the treatment of MS and type 2 diabetes mellitus is metformin, which is an antihyperglycemic agent. This drug has been shown to produce neuroprotection and to improve memory processes. However, the mechanism involved in this neuroprotection is unknown. A 90‐day administration of metformin improved the cognitive processes of rats with MS as evaluated by the novel object recognition test, and this finding could be explained by an increase in the neuronal spine density and spine length. We also found that metformin increased the immunoreactivity of synaptophysin, sirtuin‐1, AMP‐activated protein kinase, and brain‐derived neuronal factor, which are important plasticity markers. We conclude that metformin is an important therapeutic agent that increases neural plasticity and protects cognitive processes. The use of this drug is important in the minimization of the damage caused by MS.


  • Open Access

    Metabolic Syndrome Exacerbates the Recognition Memory Impairment and Oxidative‐Inflammatory Response in Rats with an Intrahippocampal Injection of Amyloid Beta 1–42

    by Alfonso Diaz, Claudia Escobedo, Samuel Treviño, Raúl Chávez, Gustavo Lopez-Lopez, Carolina Moran, Jorge Guevara, Berenice Venegas, Guadalupe Muñoz-Arenas

    An important worldwide health problem as the result of current lifestyle is metabolic syndrome (MS). It has been shown that MS induced by a high‐calorie diet (HCD) in rats produces cognitive deterioration in the novel object recognition test (NORt) and decreases synaptic connections and dendritic order in the hippocampus and temporal cortex. However, it is unknown whether MS induced by an HCD participates in the cognitive process observed with the injection of Aβ1–42 into the hippocampus of rats as a model of Alzheimer disease (AD). The induction of MS in rats produces a deterioration in NORt; however, rats with MS injected with Aβ1–42 show a major deterioration in the cognitive process. This event could be explained by the increment in the oxidative stress in both cases studied (MS and Aβ1–42): together, the hippocampus and temporal cortex produce an enhancer effect. In the same way, we observed an increment in interleukin‐1β, TNF‐α, and GFAP, indicative of exacerbated inflammatory processes by the combination of MS and Aβ1–42. We can conclude that MS might play a key role in the apparition and development of cognitive disorders, including AD. We propose that metabolic theory is important to explain the apparition of cognitive diseases.


  • Cannabinoid CB1 receptors activation and coactivation with D2 receptors modulate GABAergic neurotransmission in the globus pallidus and increase motor asymmetry

    by Guadalupe Muñoz‐Arenas, Francisco Paz‐Bermúdez, Ana Báez‐Cordero, René Caballero‐Florán, Brenda González‐Hernández, Benjamín Florán, I. Daniel Limón

    The cannabinoid CB1 (CB1R) and dopaminergic D2 (D2R) receptors modify GABAergic transmission in the globus pallidus. Although dopaminergic denervation produces changes in the expression and supersensitization of these receptors, the consequences of these changes on GABAergic neurotransmission are unknown. The aim of this study was to show the effects of CB1R and D2R activation and coactivation on the uptake and release of [3H]GABA in the globus pallidus of hemiparkinsonian rats as well as their effects on motor behavior. The activation of CB1R blocked GABA uptake and decreased GABA release in the globus pallidus in the dopamine denervated side, whereas the co‐activation of CB1R‐D2R increased GABA release and had no effect on GABA uptake. A microinjection of the CB1R agonist ACEA into the globus pallidus ipsilaterally to a 6‐OHDA lesion potentiated turning behavior that was induced by methamphetamine. However, a microinjection of the D2R agonist quinpirole did not modify this behavior, and a microinjection of a mixture of CB1R and D2R agonists significantly potentiated turning behavior. The behavioral effects produced after the activation of the CB1R and the co‐activation of CB1R and D2R can be explained by increased GABAergic neurotransmission produced by a block of GABA uptake and an increase in the release of GABA in the globus pallidus, respectively. Synapse 69:103–114, 2015.